Image courtesy of Roxwood Medical
January 7, 2016 — Roxwood Medical Inc. reported that more than 500 patients have been successfully treated as part of the initial limited release of its MicroCross Catheter, the latest addition to Roxwood Medical’s expanding product line. The MicroCross Catheter is U.S. Food and Drug Administration (FDA)-cleared and offered in two sizes (Micro14 and Micro18) for use in the coronary and peripheral vasculatures, providing enhanced guidewire support through challenging and tortuous anatomy.
Compatible with Roxwood Medical’s CenterCross Catheter, MicroCross is comprised of an ultra-low profile shaft featuring variable pitch braid technology and a state-of-the-art lubricious coating. These features allow for enhanced trackability and guidewire support while navigating tortuous regions of the coronary and peripheral vasculature.
“I have been impressed with the performance of the catheter in my early experience,” stated Jeff Moses, M.D., of Columbia University Medical Center. “The increased complexity of our treatment approach for coronary occlusions puts a lot of demand on the tools we use. The low profile and trackability of Micro14 provides an exciting new tool for us to access and cross these highly complex lesions.”
“Since first using the Micro14 and Micro18, we continue to be struck by the performance of the catheters, which have quickly become an essential part of our Critical Limb Ischemia toolkit,” said Fadi Saab, M.D., of Metro Heart Hospital, Wyoming, Mich. “These are now our frontline tools to navigate across difficult lower extremity blockages, leading to effective treatment of our patients’ severe peripheral arterial disease (PAD).”
For more information: www.roxwoodmedical.com